{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T09:23:17Z","timestamp":1790760197439,"version":"4.1.0"},"reference-count":191,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1016\/j.critrevonc.2022.103681","type":"journal-article","created":{"date-parts":[[2022,4,21]],"date-time":"2022-04-21T21:33:44Z","timestamp":1650576824000},"page":"103681","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"special_numbering":"C","title":["The HER family as therapeutic targets in colorectal cancer"],"prefix":"10.1016","volume":"174","author":[{"given":"Peng","family":"Ye","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiran","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruiqi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanlu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Wan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peiling","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.critrevonc.2022.103681_bib1","first-page":"3520","article-title":"Phase Ib study of safety and pharmacokinetics of the PI3K inhibitor SAR245408 with the HER3-neutralizing human antibody SAR256212 in patients with solid tumors","volume":"23","author":"Abramson","year":"2017","journal-title":"Clin. Res."},{"key":"10.1016\/j.critrevonc.2022.103681_bib2","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S2468-1253(17)30394-1","article-title":"Inhibition of EGFR, HER2, and HER3 signalling in patients with colorectal cancer wild-type for BRAF, PIK3CA, KRAS, and NRAS (FOCUS4-D): a phase 2-3 randomised trial","volume":"3","author":"Adams","year":"2018","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"10.1016\/j.critrevonc.2022.103681_bib3","article-title":"Phase II trial of trametinib and panitumumab in RAS\/RAF wild type metastatic colorectal cancer","author":"Alshammari","year":"2021","journal-title":"Clin. Colorectal Cancer"},{"key":"10.1016\/j.critrevonc.2022.103681_bib4","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1200\/JCO.2007.14.7116","article-title":"Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer","volume":"26","author":"Amado","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2022.103681_bib5","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1042\/BJ20120724","article-title":"HER3 signalling is regulated through a multitude of redundant mechanisms in HER2-driven tumour cells","volume":"447","author":"Amin","year":"2012","journal-title":"Biochem. J."},{"key":"10.1016\/j.critrevonc.2022.103681_bib6","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1136\/jcp.45.8.726","article-title":"HER2 (c-erbB-2) oncoprotein expression in colorectal adenocarcinoma: an immunohistological study using three different antibodies","volume":"45","author":"Arnaout","year":"1992","journal-title":"J. Clin. Pathol."},{"key":"10.1016\/j.critrevonc.2022.103681_bib7","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1002\/ijc.32618","article-title":"CD16-158-valine chimeric receptor T cells overcome the resistance of KRAS-mutated colorectal carcinoma cells to cetuximab","volume":"146","author":"Arriga","year":"2020","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.critrevonc.2022.103681_bib8","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/S0140-6736(10)61121-X","article-title":"Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial","volume":"376","author":"Bang","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.critrevonc.2022.103681_bib9","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1158\/2159-8290.CD-12-0558","article-title":"Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer","volume":"3","author":"Bardelli","year":"2013","journal-title":"Cancer Discov."},{"key":"10.1016\/j.critrevonc.2022.103681_bib10","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1200\/JCO.2009.24.2024","article-title":"Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy","volume":"28","author":"Baselga","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2022.103681_bib11","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1200\/JCO.1996.14.3.737","article-title":"Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2\/neu-overexpressing metastatic breast cancer","volume":"14","author":"Baselga","year":"1996","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2022.103681_bib12","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.737311","article-title":"The right partner in crime: unlocking the potential of the anti-EGFR antibody cetuximab via combination with natural killer cell chartering immunotherapeutic strategies","volume":"12","author":"Baysal","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.critrevonc.2022.103681_bib13","doi-asserted-by":"crossref","first-page":"329","DOI":"10.6004\/jnccn.2021.0012","article-title":"Colon cancer, version 2.2021, NCCN clinical practice guidelines in oncology","volume":"19","author":"Benson","year":"2021","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"10.1016\/j.critrevonc.2022.103681_bib14","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1158\/2159-8290.CD-11-0109","article-title":"A molecularly annotated platform of patient-derived xenografts (\u201cxenopatients\u201d) identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer","volume":"1","author":"Bertotti","year":"2011","journal-title":"Cancer Discov."},{"key":"10.1016\/j.critrevonc.2022.103681_bib15","first-page":"337","article-title":"A randomized, phase II trial of cetuximab with or without PX-866, an irreversible oral phosphatidylinositol 3-kinase inhibitor, in patients with metastatic colorectal Carcinoma","volume":"15","author":"Bowles","year":"2016","journal-title":"Clin. Colorectal Cancer"},{"key":"10.1016\/j.critrevonc.2022.103681_bib16","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1001\/archsurg.1986.01400110028004","article-title":"Increased expression of the epidermal growth factor receptor on human colon carcinoma cells","volume":"121","author":"Bradley","year":"1986","journal-title":"Arch. Surg."},{"key":"10.1016\/j.critrevonc.2022.103681_bib17","doi-asserted-by":"crossref","first-page":"3072","DOI":"10.1158\/1078-0432.CCR-16-2203","article-title":"Human papillomavirus regulates HER3 expression in head and neck cancer: implications for targeted HER3 therapy in HPV(+) patients","volume":"23","author":"Brand","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2022.103681_bib18","doi-asserted-by":"crossref","first-page":"15365","DOI":"10.1038\/s41598-019-51981-5","article-title":"Genomic characterization of intrinsic and acquired resistance to cetuximab in colorectal cancer patients","volume":"9","author":"Bray","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.critrevonc.2022.103681_bib19","first-page":"236","article-title":"First MAb approved for treatment of metastatic breast cancer","volume":"39","author":"Brenner","year":"1999","journal-title":"J. Am. Pharm. Assoc."},{"key":"10.1016\/j.critrevonc.2022.103681_bib20","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1158\/1535-7163.MCT-06-0462","article-title":"Loss of homotypic cell adhesion by epithelial-mesenchymal transition or mutation limits sensitivity to epidermal growth factor receptor inhibition","volume":"6","author":"Buck","year":"2007","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.critrevonc.2022.103681_bib21","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1007\/s10549-016-3698-y","article-title":"Effective treatment of HER2-amplified breast cancer by targeting HER3 and beta1 integrin","volume":"155","author":"Campbell","year":"2016","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.critrevonc.2022.103681_bib22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejca.2020.07.010","article-title":"AXL is a predictor of poor survival and of resistance to anti-EGFR therapy in RAS wild-type metastatic colorectal cancer","volume":"138","author":"Cardone","year":"2020","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.critrevonc.2022.103681_bib23","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1038\/276409a0","article-title":"Epidermal growth factor stimulates phosphorylation in membrane preparations in vitro","volume":"276","author":"Carpenter","year":"1978","journal-title":"Nature."},{"key":"10.1016\/j.critrevonc.2022.103681_bib24","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1146\/annurev.bi.56.070187.004313","article-title":"Receptors for epidermal growth factor and other polypeptide mitogens","volume":"56","author":"Carpenter","year":"1987","journal-title":"Ann. Rev. Biochem."},{"key":"10.1016\/j.critrevonc.2022.103681_bib25","doi-asserted-by":"crossref","first-page":"14303","DOI":"10.1016\/S0021-9258(17)36789-3","article-title":"The erbB3 gene product is a receptor for heregulin","volume":"269","author":"Carraway","year":"1994","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.critrevonc.2022.103681_bib26","doi-asserted-by":"crossref","first-page":"4285","DOI":"10.1073\/pnas.89.10.4285","article-title":"Humanization of an anti-p185HER2 antibody for human cancer therapy","volume":"89","author":"Carter","year":"1992","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.critrevonc.2022.103681_bib27","doi-asserted-by":"crossref","first-page":"5107","DOI":"10.7150\/thno.44705","article-title":"Combinative treatment of beta-elemene and cetuximab is sensitive to KRAS mutant colorectal cancer cells by inducing ferroptosis and inhibiting epithelial-mesenchymal transformation","volume":"10","author":"Chen","year":"2020","journal-title":"Theranostics."},{"key":"10.1016\/j.critrevonc.2022.103681_bib28","first-page":"4735","article-title":"The emerging role of long non-coding RNAs in the drug resistance of colorectal cancer","volume":"11","author":"Chen","year":"2018","journal-title":"Int. J. Clin. Exp. Pathol."},{"key":"10.1016\/j.critrevonc.2022.103681_bib29","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1038\/nature01392","article-title":"Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab","volume":"421","author":"Cho","year":"2003","journal-title":"Nature."},{"key":"10.1016\/j.critrevonc.2022.103681_bib30","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1042\/BST20140043","article-title":"A role for the pseudokinase HER3 in the acquired resistance against EGFR- and HER2-directed targeted therapy","volume":"42","author":"Claus","year":"2014","journal-title":"Biochem. Soc. Trans."},{"key":"10.1016\/j.critrevonc.2022.103681_bib31","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1007\/s10637-016-0399-7","article-title":"A phase 1 study combining the HER3 antibody seribantumab (MM-121) and cetuximab with and without irinotecan","volume":"35","author":"Cleary","year":"2017","journal-title":"Investig. New Drugs"},{"issue":"Pt A","key":"10.1016\/j.critrevonc.2022.103681_bib32","first-page":"557","article-title":"Epidermal growth factor-receptor-protein kinase interactions","volume":"66","author":"Cohen","year":"1981","journal-title":"Prog. Clin. Biol. Res."},{"key":"10.1016\/j.critrevonc.2022.103681_bib33","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1634\/theoncologist.8-4-303","article-title":"FDA drug approval summary: gefitinib (ZD1839) (Iressa) tablets","volume":"8","author":"Cohen","year":"2003","journal-title":"Oncologist"},{"key":"10.1016\/j.critrevonc.2022.103681_bib34","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1016\/S0021-9258(19)83739-0","article-title":"Isolation of a mouse submaxillary gland protein accelerating incisor eruption and eyelid opening in the new-born animal","volume":"237","author":"Cohen","year":"1962","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.critrevonc.2022.103681_bib35","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1111\/1523-1747.ep12625690","article-title":"Epidermal growth factor","volume":"59","author":"Cohen","year":"1972","journal-title":"J. Investig. Dermatol."},{"key":"10.1016\/j.critrevonc.2022.103681_bib36","doi-asserted-by":"crossref","first-page":"345","DOI":"10.3390\/biomedicines2040345","article-title":"Role of HGF-MET signaling in primary and acquired resistance to targeted therapies in cancer","volume":"2","author":"Della Corte","year":"2014","journal-title":"Biomedicines."},{"key":"10.1016\/j.critrevonc.2022.103681_bib37","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1056\/NEJMoa033025","article-title":"Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer","volume":"351","author":"Cunningham","year":"2004","journal-title":"New Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2022.103681_bib38","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1158\/1078-0432.CCR-14-2313","article-title":"Gene expression markers of efficacy and resistance to cetuximab treatment in metastatic colorectal cancer: results from CALGB 80203 (Alliance)","volume":"21","author":"Cushman","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2022.103681_bib39","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1007\/s40265-017-0811-4","article-title":"Neratinib: first global approval","volume":"77","author":"Deeks","year":"2017","journal-title":"Drugs"},{"key":"10.1016\/j.critrevonc.2022.103681_bib40","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1007\/s10637-021-01145-y","article-title":"Phase 1 dose escalation study of seribantumab (MM-121), an anti-HER3 monoclonal antibody, in patients with advanced solid tumors","volume":"39","author":"Denlinger","year":"2021","journal-title":"Investig. New Drugs"},{"key":"10.1016\/j.critrevonc.2022.103681_bib41","doi-asserted-by":"crossref","first-page":"e149","DOI":"10.14694\/EdBook_AM.2015.35.e149","article-title":"Overcoming resistance to anti-EGFR therapy in colorectal cancer","author":"Dienstmann","year":"2015","journal-title":"American Society of Clinical Oncology educational book American Society of Clinical Oncology Annual Meeting"},{"key":"10.1016\/j.critrevonc.2022.103681_bib42","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1056\/NEJMoa1305275","article-title":"Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer","volume":"369","author":"Douillard","year":"2013","journal-title":"New Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2022.103681_bib43","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1038\/307521a0","article-title":"Close similarity of epidermal growth factor receptor and v-erb-B oncogene protein sequences","volume":"307","author":"Downward","year":"1984","journal-title":"Nature."},{"key":"10.1016\/j.critrevonc.2022.103681_bib44","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/S0092-8674(85)80050-7","article-title":"Down-modulation of an oncogene protein product and reversion of the transformed phenotype by monoclonal antibodies","volume":"41","author":"Drebin","year":"1985","journal-title":"Cell."},{"key":"10.1016\/j.critrevonc.2022.103681_bib45","first-page":"315","article-title":"The EGF receptor family--multiple roles in proliferation, differentiation, and neoplasia with an emphasis on HER4","volume":"114","author":"Earp","year":"2003","journal-title":"Trans. Am. Clin. Climatol. Assoc."},{"key":"10.1016\/j.critrevonc.2022.103681_bib46","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1200\/JCO.2005.01.8960","article-title":"Phase I study of EKB-569, an irreversible inhibitor of the epidermal growth factor receptor, in patients with advanced solid tumors","volume":"24","author":"Erlichman","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2022.103681_bib47","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2013.337","article-title":"Cancer-initiating cells derived from human rectal adenocarcinoma tissues carry mesenchymal phenotypes and resist drug therapies","volume":"4","author":"Fan","year":"2013","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.critrevonc.2022.103681_bib48","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1016\/0092-8674(87)90592-7","article-title":"Overexpression of the human EGF receptor confers an EGF-dependent transformed phenotype to NIH 3T3 cells","volume":"51","author":"Di Fiore","year":"1987","journal-title":"Cell."},{"key":"10.1016\/j.critrevonc.2022.103681_bib49","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1126\/science.2885917","article-title":"erbB-2 is a potent oncogene when overexpressed in NIH\/3T3 cells","volume":"237","author":"Di Fiore","year":"1987","journal-title":"Science."},{"key":"10.1016\/j.critrevonc.2022.103681_bib50","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.ejca.2019.08.017","article-title":"Patritumab or placebo, with cetuximab plus platinum therapy in recurrent or metastatic squamous cell carcinoma of the head and neck: a randomised phase II study","volume":"123","author":"Forster","year":"2019","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.critrevonc.2022.103681_bib51","doi-asserted-by":"crossref","DOI":"10.1158\/2326-6074.TUMIMM19-B65","article-title":"Abstract B65: CT-0508, a novel CAR macrophage product directed against HER2, promotes a proinflammatory tumor microenvironment","volume":"8","author":"Gabrusiewicz","year":"2020","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.critrevonc.2022.103681_bib52","doi-asserted-by":"crossref","DOI":"10.1002\/onco.13860","article-title":"A phase I, first-in-human study of GSK2849330, an Anti-HER3 monoclonal antibody, in HER3-expressing solid tumors","author":"Gan","year":"2021","journal-title":"Oncologist"},{"key":"10.1016\/j.critrevonc.2022.103681_bib53","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/S1097-2765(03)00048-0","article-title":"The crystal structure of a truncated ErbB2 ectodomain reveals an active conformation, poised to interact with other ErbB receptors","volume":"11","author":"Garrett","year":"2003","journal-title":"Mol. Cell"},{"key":"10.1016\/j.critrevonc.2022.103681_bib54","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1634\/theoncologist.12-5-577","article-title":"FDA drug approval summary: panitumumab (Vectibix)","volume":"12","author":"Giusti","year":"2007","journal-title":"Oncologist"},{"key":"10.1016\/j.critrevonc.2022.103681_bib55","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.18632\/oncotarget.26663","article-title":"Broad-spectrum receptor tyrosine kinase inhibitors overcome de novo and acquired modes of resistance to EGFR-targeted therapies in colorectal cancer","volume":"10","author":"Graves-Deal","year":"2019","journal-title":"Oncotarget."},{"issue":"1","key":"10.1016\/j.critrevonc.2022.103681_bib56","first-page":"14","article-title":"HER-2 breast assay, linked to Herceptin, wins FDA\u2019s okay","volume":"12","author":"Graziano","year":"1998","journal-title":"CAP Today"},{"key":"10.1016\/j.critrevonc.2022.103681_bib57","doi-asserted-by":"crossref","first-page":"8132","DOI":"10.1073\/pnas.91.17.8132","article-title":"Insect cell-expressed p180erbB3 possesses an impaired tyrosine kinase activity","volume":"91","author":"Guy","year":"1994","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.critrevonc.2022.103681_bib58","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1200\/JCO.2017.75.3780","article-title":"Targeted therapy for advanced solid tumors on the basis of molecular profiles: results from mypathway, an open-label, phase IIa multiple basket study","volume":"36","author":"Hainsworth","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2022.103681_bib59","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.SABCS18-P6-17-13","article-title":"Abstract P6-17-13: ZW49, a HER2 targeted biparatopic antibody drug conjugate for the treatment of HER2 expressing cancers","volume":"79","author":"Hamblett","year":"2019","journal-title":"Cancer Res."},{"key":"10.1016\/j.critrevonc.2022.103681_bib60","doi-asserted-by":"crossref","first-page":"7151","DOI":"10.1158\/1078-0432.CCR-19-1745","article-title":"A Novel HER3-targeting antibody-drug conjugate, U3-1402, exhibits potent therapeutic efficacy through the delivery of cytotoxic payload by efficient internalization","volume":"25","author":"Hashimoto","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2022.103681_bib61","doi-asserted-by":"crossref","first-page":"ra116","DOI":"10.1126\/scisignal.2005770","article-title":"Neuregulin 1-activated ERBB4 interacts with YAP to induce Hippo pathway target genes and promote cell migration","volume":"7","author":"Haskins","year":"2014","journal-title":"Sci. Signal."},{"key":"10.1016\/j.critrevonc.2022.103681_bib62","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1200\/JCO.2008.19.8135","article-title":"A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer","volume":"27","author":"Hecht","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2022.103681_bib63","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1158\/1078-0432.CCR-09-2017","article-title":"Lack of correlation between epidermal growth factor receptor status and response to Panitumumab monotherapy in metastatic colorectal cancer","volume":"16","author":"Hecht","year":"2010","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"10.1016\/j.critrevonc.2022.103681_bib64","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1172\/JCI111463","article-title":"Human squamous cell lung cancers express increased epidermal growth factor receptors","volume":"74","author":"Hendler","year":"1984","journal-title":"Journal Clin. Investig."},{"key":"10.1016\/j.critrevonc.2022.103681_bib65","doi-asserted-by":"crossref","first-page":"2276","DOI":"10.1158\/1078-0432.CCR-17-0646","article-title":"Phase II study of the dual EGFR\/HER3 inhibitor duligotuzumab (MEHD7945A) versus cetuximab in combination with FOLFIRI in second-line RAS wild-type metastatic colorectal cancer","volume":"24","author":"Hill","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2022.103681_bib66","doi-asserted-by":"crossref","first-page":"6429","DOI":"10.1158\/1078-0432.CCR-14-0774","article-title":"TGFalpha and amphiregulin paracrine network promotes resistance to EGFR blockade in colorectal cancer cells","volume":"20","author":"Hobor","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2022.103681_bib67","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1126\/science.256.5060.1205","article-title":"Identification of heregulin, a specific activator of p185erbB2","volume":"256","author":"Holmes","year":"1992","journal-title":"Science"},{"key":"10.1016\/j.critrevonc.2022.103681_bib68","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1158\/0008-5472.CAN-12-1611","article-title":"Dual targeting of EGFR and HER3 with MEHD7945A overcomes acquired resistance to EGFR inhibitors and radiation","volume":"73","author":"Huang","year":"2013","journal-title":"Cancer Res."},{"key":"10.1016\/j.critrevonc.2022.103681_bib69","first-page":"1165","article-title":"p185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor","volume":"9","author":"Hudziak","year":"1989","journal-title":"Mol. Cell. Biol."},{"key":"10.1016\/j.critrevonc.2022.103681_bib70","doi-asserted-by":"crossref","first-page":"7159","DOI":"10.1073\/pnas.84.20.7159","article-title":"Increased expression of the putative growth factor receptor p185HER2 causes transformation and tumorigenesis of NIH 3T3 cells","volume":"84","author":"Hudziak","year":"1987","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.critrevonc.2022.103681_bib71","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1046\/j.1525-1438.1995.05040282.x","article-title":"c-erbB-3 proto-oncogene expression in uterine cervical carcinoma","volume":"5","author":"Hunt","year":"1995","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.critrevonc.2022.103681_bib72","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1093\/jjco\/hys012","article-title":"Safety, efficacy and pharmacokinetics of neratinib (HKI-272) in Japanese patients with advanced solid tumors: a Phase 1 dose-escalation study","volume":"42","author":"Ito","year":"2012","journal-title":"Japan. J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2022.103681_bib73","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1158\/1078-0432.CCR-20-1831","article-title":"Neratinib-Plus-Cetuximab in Quadruple-WT (KRAS, NRAS, BRAF, PIK3CA) Metastatic Colorectal Cancer Resistant to Cetuximab or Panitumumab: NSABP FC-7, A Phase Ib Study","volume":"27","author":"Jacobs","year":"2021","journal-title":"Clin. Cancer Res. Offi. J. American Association Cancer Res."},{"key":"10.1016\/j.critrevonc.2022.103681_bib74","doi-asserted-by":"crossref","first-page":"5901","DOI":"10.1158\/0008-5472.CAN-10-0192","article-title":"Genomic and biological characterization of exon 4 KRAS mutations in human cancer","volume":"70","author":"Janakiraman","year":"2010","journal-title":"Cancer Res."},{"key":"10.1016\/j.critrevonc.2022.103681_bib75","article-title":"Efficacy and safety of patritumab deruxtecan (HER3-DXd) in EGFR inhibitor-resistant, EGFR-mutated non-small cell lung cancer","author":"Janne","year":"2021","journal-title":"Cancer Discov."},{"key":"10.1016\/j.critrevonc.2022.103681_bib76","doi-asserted-by":"crossref","first-page":"2986","DOI":"10.1002\/ijc.22257","article-title":"ERBB3 kinase domain mutations are rare in lung, breast and colon carcinomas","volume":"119","author":"Jeong","year":"2006","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.critrevonc.2022.103681_bib77","first-page":"1779","article-title":"HER4 promotes the progression of colorectal cancer by promoting epithelialmesenchymal transition","volume":"21","author":"Jia","year":"2020","journal-title":"Mol. Med. Rep."},{"key":"10.1016\/j.critrevonc.2022.103681_bib78","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.ccr.2009.03.020","article-title":"Ligand-independent HER2\/HER3\/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941","volume":"15","author":"Junttila","year":"2009","journal-title":"Cancer Cell"},{"key":"10.1016\/j.critrevonc.2022.103681_bib79","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1158\/1078-0432.CCR-14-2412","article-title":"Safety and pharmacokinetics\/pharmacodynamics of the first-in-class dual action HER3\/EGFR antibody MEHD7945A in locally advanced or metastatic epithelial tumors","volume":"21","author":"Juric","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2022.103681_bib80","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1056\/NEJMoa0804385","article-title":"K-ras mutations and benefit from cetuximab in advanced colorectal cancer","volume":"359","author":"Karapetis","year":"2008","journal-title":"New Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2022.103681_bib81","doi-asserted-by":"crossref","first-page":"11847","DOI":"10.18632\/oncotarget.2663","article-title":"The anti-HER3 antibody patritumab abrogates cetuximab resistance mediated by heregulin in colorectal cancer cells","volume":"5","author":"Kawakami","year":"2014","journal-title":"Oncotarget."},{"key":"10.1016\/j.critrevonc.2022.103681_bib82","doi-asserted-by":"crossref","first-page":"267","DOI":"10.2174\/1574892811666160418123221","article-title":"HER3 and its ligand, heregulin, as targets for cancer therapy","volume":"11","author":"Kawakami","year":"2016","journal-title":"Recent Patents Anti cancer Drug Discov."},{"key":"10.1016\/j.critrevonc.2022.103681_bib83","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1007\/s40265-020-01281-4","article-title":"Trastuzumab deruxtecan: first approval","volume":"80","author":"Keam","year":"2020","journal-title":"Drugs."},{"key":"10.1016\/j.critrevonc.2022.103681_bib84","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4251\/wjgo.v8.i1.1","article-title":"Clinical efficacy and drug resistance of anti-epidermal growth factor receptor therapy in colorectal cancer","volume":"8","author":"Kocoglu","year":"2016","journal-title":"World J. Gastrointest. Oncol."},{"key":"10.1016\/j.critrevonc.2022.103681_bib85","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1158\/1535-7163.MCT-19-0452","article-title":"U3-1402, a Novel HER3-Targeting Antibody-Drug Conjugate, for the Treatment of Colorectal Cancer","volume":"18","author":"Koganemaru","year":"2019","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.critrevonc.2022.103681_bib86","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2019-000624","article-title":"BIG BANG study (EPOC1703): multicentre, proof-of-concept, phase II study evaluating the efficacy and safety of combination therapy with binimetinib, encorafenib and cetuximab in patients with BRAF non-V600E mutated metastatic colorectal cancer","volume":"5","author":"Kotani","year":"2020","journal-title":"ESMO Open"},{"key":"10.1016\/j.critrevonc.2022.103681_bib87","doi-asserted-by":"crossref","first-page":"9193","DOI":"10.1073\/pnas.86.23.9193","article-title":"Isolation and characterization of ERBB3, a third member of the ERBB\/epidermal growth factor receptor family: evidence for overexpression in a subset of human mammary tumors","volume":"86","author":"Kraus","year":"1989","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.critrevonc.2022.103681_bib88","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1002\/j.1460-2075.1987.tb04797.x","article-title":"Overexpression of the EGF receptor-related proto-oncogene erbB-2 in human mammary tumor cell lines by different molecular mechanisms","volume":"6","author":"Kraus","year":"1987","journal-title":"EMBO J."},{"key":"10.1016\/j.critrevonc.2022.103681_bib89","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/bs.acr.2020.04.001","article-title":"HER family in cancer progression: From discovery to 2020 and beyond","volume":"147","author":"Kumar","year":"2020","journal-title":"Adv. Cancer Res."},{"key":"10.1016\/j.critrevonc.2022.103681_bib90","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.annonc.2019.09.004","article-title":"Randomized, double-blind, placebo-controlled phase II study of istiratumab (MM-141) plus nab-paclitaxel and gemcitabine versus nab-paclitaxel and gemcitabine in front-line metastatic pancreatic cancer (CARRIE)","volume":"31","author":"Kundranda","year":"2020","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2022.103681_bib91","article-title":"Zanidatamab, an anti-HER2 bispecific antibody, plus chemotherapy with\/without tislelizumab as first-line treatment for patients with advanced HER2-positive breast cancer or gastric\/gastroesophageal junction adenocarcinoma: a phase 1B\/2 trial-in-progress","volume":"39","author":"Lee","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2022.103681_bib92","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1038\/bjc.1992.420","article-title":"Expression of the ERBB3 gene product in breast cancer","volume":"66","author":"Lemoine","year":"1992","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.critrevonc.2022.103681_bib93","doi-asserted-by":"crossref","first-page":"5519","DOI":"10.1158\/1078-0432.CCR-14-3066","article-title":"Sustained inhibition of HER3 and EGFR Is necessary to induce regression of HER2-amplified gastrointestinal carcinomas","volume":"21","author":"Leto","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2022.103681_bib94","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1186\/s12935-021-01829-8","article-title":"Identification of key genes involved in tumor immune cell infiltration and cetuximab resistance in colorectal cancer","volume":"21","author":"Liang","year":"2021","journal-title":"Cancer Cell Int."},{"key":"10.1016\/j.critrevonc.2022.103681_bib95","first-page":"1697","article-title":"CAN017, a novel anti-HER3 antibody, exerted great potency in mouse avatars of esophageal squamous cell carcinoma with NRG1 as a biomarker","volume":"11","author":"Liao","year":"2021","journal-title":"Am. J. Cancer Res."},{"key":"10.1016\/j.critrevonc.2022.103681_bib96","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1038\/313144a0","article-title":"Amplification, enhanced expression and possible rearrangement of EGF receptor gene in primary human brain tumours of glial origin","volume":"313","author":"Libermann","year":"1985","journal-title":"Nature."},{"key":"10.1016\/j.critrevonc.2022.103681_bib97","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1634\/theoncologist.2017-0175","article-title":"A phase ib dose-escalation study of the safety, tolerability, and pharmacokinetics of cobimetinib and duligotuzumab in patients with previously treated locally advanced or metastatic cancers with mutant KRAS","volume":"22","author":"Lieu","year":"2017","journal-title":"Oncologist"},{"key":"10.1016\/j.critrevonc.2022.103681_bib98","doi-asserted-by":"crossref","first-page":"3992","DOI":"10.1158\/0008-5472.CAN-06-0191","article-title":"KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer","volume":"66","author":"Lievre","year":"2006","journal-title":"Cancer Res."},{"key":"10.1016\/j.critrevonc.2022.103681_bib99","first-page":"3735","article-title":"Silencing Smad4 attenuates sensitivity of colorectal cancer cells to cetuximab by promoting epithelialmesenchymal transition","volume":"20","author":"Lin","year":"2019","journal-title":"Mol. Med. Rep."},{"key":"10.1016\/j.critrevonc.2022.103681_bib100","article-title":"A first in-human study of A166 in patients with locally advanced\/metastatic solid tumors which are HER2-positive or HER2-amplified who did not respond or stopped responding to approved therapies","volume":"38","author":"Liu","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2022.103681_bib101","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s12575-019-0093-1","article-title":"Development of effective therapeutics targeting HER3 for cancer treatment","volume":"21","author":"Liu","year":"2019","journal-title":"Biol. Proced. Online"},{"key":"10.1016\/j.critrevonc.2022.103681_bib102","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/s12943-022-01555-3","article-title":"Interaction of lncRNA MIR100HG with hnRNPA2B1 facilitates m(6)A-dependent stabilization of TCF7L2 mRNA and colorectal cancer progression","volume":"21","author":"Liu","year":"2022","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.critrevonc.2022.103681_bib103","doi-asserted-by":"crossref","first-page":"4345","DOI":"10.1200\/JCO.2016.67.1891","article-title":"Randomized phase II trial of seribantumab in combination with paclitaxel in patients with advanced platinum-resistant or -refractory ovarian cancer","volume":"34","author":"Liu","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2022.103681_bib104","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.lungcan.2021.05.011","article-title":"NRG1 fusions: biology to therapy","volume":"158","author":"Liu","year":"2021","journal-title":"Lung Cancer"},{"key":"10.1016\/j.critrevonc.2022.103681_bib105","article-title":"Abstract 2169: ACE1702: a potent and off-the-shelf oNK cell therapy product","volume":"80","author":"Li","year":"2020","journal-title":"Cancer Res."},{"key":"10.1016\/j.critrevonc.2022.103681_bib106","doi-asserted-by":"crossref","first-page":"3078","DOI":"10.1158\/1078-0432.CCR-12-3051","article-title":"Phase I Study of U3-1287, a fully human anti-HER3 monoclonal antibody, in patients with advanced solid tumors","volume":"19","author":"LoRusso","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2022.103681_bib107","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1038\/sj.bjc.6605177","article-title":"KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer","volume":"101","author":"Loupakis","year":"2009","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.critrevonc.2022.103681_bib108","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1158\/0008-5472.CAN-13-2340-T","article-title":"MET signaling in colon cancer stem-like cells blunts the therapeutic response to EGFR inhibitors","volume":"74","author":"Luraghi","year":"2014","journal-title":"Cancer Res."},{"key":"10.1016\/j.critrevonc.2022.103681_bib109","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1053\/sonc.2002.31522","article-title":"Therapeutic potential of ABX-EGF: a fully human anti-epidermal growth factor receptor monoclonal antibody for cancer treatment","volume":"29","author":"Lynch","year":"2002","journal-title":"Semin. Oncol."},{"key":"10.1016\/j.critrevonc.2022.103681_bib110","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2020.102023","article-title":"Resistance to anti-epidermal growth factor receptor in metastatic colorectal cancer: what does still need to be addressed?","volume":"86","author":"Martini","year":"2020","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.critrevonc.2022.103681_bib111","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1038\/bjc.2013.4","article-title":"HER2 gene copy number status may influence clinical efficacy to anti-EGFR monoclonal antibodies in metastatic colorectal cancer patients","volume":"108","author":"Martin","year":"2013","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.critrevonc.2022.103681_bib112","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1186\/1476-4598-13-105","article-title":"Targeting of erbB3 receptor to overcome resistance in cancer treatment","volume":"13","author":"Ma","year":"2014","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.critrevonc.2022.103681_bib113","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1158\/1535-7163.MCT-11-0820","article-title":"Antitumor activity of a novel bispecific antibody that targets the ErbB2\/ErbB3 oncogenic unit and inhibits heregulin-induced activation of ErbB3","volume":"11","author":"McDonagh","year":"2012","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.critrevonc.2022.103681_bib114","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/S1470-2045(18)30904-5","article-title":"Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study","volume":"20","author":"Meric-Bernstam","year":"2019","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2022.103681_bib115","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1158\/1078-0432.CCR-15-1683","article-title":"First-in-human phase I study of lumretuzumab, a glycoengineered humanized Anti-HER3 monoclonal antibody, in patients with metastatic or advanced HER3-positive solid tumors","volume":"22","author":"Meulendijks","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2022.103681_bib116","doi-asserted-by":"crossref","first-page":"5406","DOI":"10.1158\/1078-0432.CCR-17-0812","article-title":"Phase Ib study of lumretuzumab plus cetuximab or erlotinib in solid tumor patients and evaluation of HER3 and heregulin as potential biomarkers of clinical activity","volume":"23","author":"Meulendijks","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2022.103681_bib117","doi-asserted-by":"crossref","DOI":"10.4161\/21624011.2014.956012","article-title":"HER-3 peptide vaccines\/mimics: combined therapy with IGF-1R, HER-2, and HER-1 peptides induces synergistic antitumor effects against breast and pancreatic cancer cells","volume":"3","author":"Miller","year":"2014","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.critrevonc.2022.103681_bib118","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1158\/2159-8290.CD-14-0462","article-title":"Resistance to anti-EGFR therapy in colorectal cancer: from heterogeneity to convergent evolution","volume":"4","author":"Misale","year":"2014","journal-title":"Cancer Discov."},{"key":"10.1016\/j.critrevonc.2022.103681_bib119","first-page":"355","article-title":"HER3 signaling and targeted therapy in cancer","volume":"12","author":"Mishra","year":"2018","journal-title":"Oncology Rev."},{"key":"10.1016\/j.critrevonc.2022.103681_bib120","unstructured":"Monoclonal antibody approved for metastatic breast cancer. Oncology (Williston Park). 1998; 12: 1727."},{"key":"10.1016\/j.critrevonc.2022.103681_bib121","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1038\/nm.2609","article-title":"Identification of a mutation in the extracellular domain of the Epidermal Growth Factor Receptor conferring cetuximab resistance in colorectal cancer","volume":"18","author":"Montagut","year":"2012","journal-title":"Nat. Med."},{"key":"10.1016\/j.critrevonc.2022.103681_bib122","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1634\/theoncologist.2016-0084","article-title":"Location of primary tumor and benefit from anti-epidermal growth factor receptor monoclonal antibodies in patients with RAS and BRAF wild-type metastatic colorectal cancer","volume":"21","author":"Moretto","year":"2016","journal-title":"Oncologist"},{"key":"10.1016\/j.critrevonc.2022.103681_bib123","doi-asserted-by":"crossref","first-page":"89284","DOI":"10.18632\/oncotarget.18467","article-title":"A comprehensive review of heregulins, HER3, and HER4 as potential therapeutic targets in cancer","volume":"8","author":"Mota","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.critrevonc.2022.103681_bib124","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0151865","article-title":"BRAF, PIK3CA, and HER2 oncogenic alterations according to KRAS mutation status in advanced colorectal cancers with distant metastasis","volume":"11","author":"Nam","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.critrevonc.2022.103681_bib125","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.bbrc.2016.01.045","article-title":"Development of an ErbB4 monoclonal antibody that blocks neuregulin-1-induced ErbB4 activation in cancer cells","volume":"470","author":"Okazaki","year":"2016","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.critrevonc.2022.103681_bib126","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1002\/jcb.22952","article-title":"Stem cell property epithelial-to-mesenchymal transition is a core transcriptional network for predicting cetuximab (Erbitux) efficacy in KRAS wild-type tumor cells","volume":"112","author":"Oliveras-Ferraros","year":"2011","journal-title":"J. Cell. Biochem."},{"key":"10.1016\/j.critrevonc.2022.103681_bib127","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.7150\/thno.30678","article-title":"Sonic hedgehog pathway activation is associated with cetuximab resistance and EPHB3 receptor induction in colorectal cancer","volume":"9","author":"Park","year":"2019","journal-title":"Theranostics."},{"key":"10.1016\/j.critrevonc.2022.103681_bib128","doi-asserted-by":"crossref","DOI":"10.1038\/s41388-021-01920-4","article-title":"EMT-mediated regulation of CXCL1\/5 for resistance to anti-EGFR therapy in colorectal cancer","author":"Park","year":"2022","journal-title":"Oncogene"},{"key":"10.1016\/j.critrevonc.2022.103681_bib129","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1158\/1078-0432.CCR-12-1913","article-title":"Massively parallel tumor multigene sequencing to evaluate response to panitumumab in a randomized phase III study of metastatic colorectal cancer","volume":"19","author":"Peeters","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2022.103681_bib130","doi-asserted-by":"crossref","first-page":"3738","DOI":"10.3748\/wjg.v20.i14.3738","article-title":"Colorectal cancer and immunity: what we know and perspectives","volume":"20","author":"Pernot","year":"2014","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.critrevonc.2022.103681_bib131","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1093\/annonc\/mdn541","article-title":"PI3KCA\/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients","volume":"20","author":"Perrone","year":"2009","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"key":"10.1016\/j.critrevonc.2022.103681_bib132","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1073\/pnas.90.5.1746","article-title":"Ligand-specific activation of HER4\/p180erbB4, a fourth member of the epidermal growth factor receptor family","volume":"90","author":"Plowman","year":"1993","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.critrevonc.2022.103681_bib133","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1038\/366473a0","article-title":"Heregulin induces tyrosine phosphorylation of HER4\/p180erbB4","volume":"366","author":"Plowman","year":"1993","journal-title":"Nature."},{"key":"10.1016\/j.critrevonc.2022.103681_bib134","doi-asserted-by":"crossref","first-page":"4905","DOI":"10.1073\/pnas.87.13.4905","article-title":"Molecular cloning and expression of an additional epidermal growth factor receptor-related gene","volume":"87","author":"Plowman","year":"1990","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.critrevonc.2022.103681_bib135","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1080\/15384047.2020.1798695","article-title":"Frequency of S492R mutations in the epidermal growth factor receptor: analysis of plasma DNA from patients with metastatic colorectal cancer treated with panitumumab or cetuximab monotherapy","volume":"21","author":"Price","year":"2020","journal-title":"Cancer Biol. Ther."},{"key":"10.1016\/j.critrevonc.2022.103681_bib136","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1081\/CNV-200039645","article-title":"Low overexpression of HER-2\/neu in advanced colorectal cancer limits the usefulness of trastuzumab (Herceptin) and irinotecan as therapy. A phase II trial","volume":"22","author":"Ramanathan","year":"2004","journal-title":"Cancer Investig."},{"key":"10.1016\/j.critrevonc.2022.103681_bib137","first-page":"125","article-title":"Phase II study of tivantinib and cetuximab in patients with KRAS wild-type metastatic colorectal cancer with acquired resistance to EGFR inhibitors and emergence of MET overexpression: lesson learned for future trials with EGFR\/MET dual inhibition","volume":"18","author":"Rimassa","year":"2019","journal-title":"Clin, Colorectal Cancer"},{"key":"10.1016\/j.critrevonc.2022.103681_bib138","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/S1470-2045(10)70130-3","article-title":"Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis","volume":"11","author":"De Roock","year":"2010","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2022.103681_bib139","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.phrs.2018.11.014","article-title":"Small molecule inhibitors targeting the EGFR\/ErbB family of protein-tyrosine kinases in human cancers","volume":"139","author":"Roskoski","year":"2019","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.critrevonc.2022.103681_bib140","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/s10637-013-9956-5","article-title":"Multi-drug inhibition of the HER pathway in metastatic colorectal cancer: results of a phase I study of pertuzumab plus cetuximab in cetuximab-refractory patients","volume":"32","author":"Rubinson","year":"2014","journal-title":"Investig. New Drugs"},{"key":"10.1016\/j.critrevonc.2022.103681_bib141","doi-asserted-by":"crossref","first-page":"3645","DOI":"10.1158\/0008-5472.CAN-18-0430","article-title":"HER2 Amplification in Tumors Activates PI3K\/Akt Signaling Independent of HER3","volume":"78","author":"Ruiz-Saenz","year":"2018","journal-title":"Cancer Res."},{"key":"10.1016\/j.critrevonc.2022.103681_bib142","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1593\/tlo.13475","article-title":"EV20, a Novel Anti-ErbB-3 Humanized Antibody, Promotes ErbB-3 Down-Regulation and Inhibits Tumor Growth In Vivo","volume":"6","author":"Sala","year":"2013","journal-title":"Transl. Oncol."},{"key":"10.1016\/j.critrevonc.2022.103681_bib143","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1200\/JCO.2004.10.182","article-title":"Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor","volume":"22","author":"Saltz","year":"2004","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2022.103681_bib144","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1002\/ijc.2910540612","article-title":"Expression of the c-erbB-3 gene product in gastric cancer","volume":"54","author":"Sanidas","year":"1993","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.critrevonc.2022.103681_bib145","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2020-000911","article-title":"Pertuzumab and trastuzumab emtansine in patients with HER2-amplified metastatic colorectal cancer: the phase II HERACLES-B trial","volume":"5","author":"Sartore-Bianchi","year":"2020","journal-title":"ESMO Open"},{"key":"10.1016\/j.critrevonc.2022.103681_bib146","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/S1470-2045(16)00150-9","article-title":"Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12\/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial","volume":"17","author":"Sartore-Bianchi","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.critrevonc.2022.103681_bib147","doi-asserted-by":"crossref","first-page":"4265","DOI":"10.1128\/MCB.21.13.4265-4275.2001","article-title":"Her4 mediates ligand-dependent antiproliferative and differentiation responses in human breast cancer cells","volume":"21","author":"Sartor","year":"2001","journal-title":"Mol. Cell. Biol."},{"key":"10.1016\/j.critrevonc.2022.103681_bib148","doi-asserted-by":"crossref","first-page":"3223","DOI":"10.1158\/1535-7163.MCT-07-2151","article-title":"Human epidermal growth factor receptor (HER-1:HER-3) Fc-mediated heterodimer has broad antiproliferative activity in vitro and in human tumor xenografts","volume":"7","author":"Sarup","year":"2008","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.critrevonc.2022.103681_bib149","first-page":"511","article-title":"Biological effects in vitro of monoclonal antibodies to human epidermal growth factor receptors","volume":"1","author":"Sato","year":"1983","journal-title":"Mol. Biol. Med."},{"key":"10.1016\/j.critrevonc.2022.103681_bib150","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1126\/science.2992090","article-title":"The neu gene: an erbB-homologous gene distinct from and unlinked to the gene encoding the EGF receptor","volume":"229","author":"Schechter","year":"1985","journal-title":"Science"},{"key":"10.1016\/j.critrevonc.2022.103681_bib151","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1038\/312513a0","article-title":"The neu oncogene: an erb-B-related gene encoding a 185,000-Mr tumour antigen","volume":"312","author":"Schechter","year":"1984","journal-title":"Nature"},{"key":"10.1016\/j.critrevonc.2022.103681_bib152","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1007\/s10637-018-0562-4","article-title":"Phase Ib study evaluating safety and clinical activity of the anti-HER3 antibody lumretuzumab combined with the anti-HER2 antibody pertuzumab and paclitaxel in HER3-positive, HER2-low metastatic breast cancer","volume":"36","author":"Schneeweiss","year":"2018","journal-title":"Investig. New Drugs"},{"key":"10.1016\/j.critrevonc.2022.103681_bib153","doi-asserted-by":"crossref","first-page":"6497","DOI":"10.1073\/pnas.82.19.6497","article-title":"A v-erbB-related protooncogene, c-erbB-2, is distinct from the c-erbB-1\/epidermal growth factor-receptor gene and is amplified in a human salivary gland adenocarcinoma","volume":"82","author":"Semba","year":"1985","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.critrevonc.2022.103681_bib154","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1634\/theoncologist.2018-0695","article-title":"Randomized phase II trial of seribantumab in combination with erlotinib in patients with EGFR wild-type non-small cell lung cancer","volume":"24","author":"Sequist","year":"2019","journal-title":"Oncologist"},{"key":"10.1016\/j.critrevonc.2022.103681_bib155","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1358\/dot.2019.55.11.3035584","article-title":"Binimetinib, encorafenib and cetuximab (BEACON Trial) combination therapy for patients with BRAF V600E-mutant metastatic colorectal cancer","volume":"55","author":"Shahjehan","year":"2019","journal-title":"Drugs Today"},{"key":"10.1016\/j.critrevonc.2022.103681_bib156","doi-asserted-by":"crossref","first-page":"7692","DOI":"10.1073\/pnas.1002753107","article-title":"ErbB3\/HER3 intracellular domain is competent to bind ATP and catalyze autophosphorylation","volume":"107","author":"Shi","year":"2010","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.critrevonc.2022.103681_bib157","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/S1470-2045(21)00086-3","article-title":"Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial","volume":"22","author":"Siena","year":"2021","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2022.103681_bib158","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1126\/science.3798106","article-title":"Human breast cancer: correlation of relapse and survival with amplification of the HER-2\/neu oncogene","volume":"235","author":"Slamon","year":"1987","journal-title":"Science."},{"key":"10.1016\/j.critrevonc.2022.103681_bib159","doi-asserted-by":"crossref","first-page":"14661","DOI":"10.1016\/S0021-9258(17)36676-0","article-title":"Coexpression of erbB2 and erbB3 proteins reconstitutes a high affinity receptor for heregulin","volume":"269","author":"Sliwkowski","year":"1994","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.critrevonc.2022.103681_bib160","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1038\/sj.bjc.6605534","article-title":"Activating K-Ras mutations outwith \u2018hotspot\u2019 codons in sporadic colorectal tumours - implications for personalised cancer medicine","volume":"102","author":"Smith","year":"2010","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.critrevonc.2022.103681_bib161","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1002\/ijc.21507","article-title":"Somatic mutations of the ERBB4 kinase domain in human cancers","volume":"118","author":"Soung","year":"2006","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.critrevonc.2022.103681_bib162","first-page":"9","article-title":"PD-L1 targeting and subclonal immune escape mediated by PD-L1 mutations in metastatic colorectal cancer","author":"Stein","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.critrevonc.2022.103681_bib163","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1002\/onco.13678","article-title":"Cabozantinib and panitumumab for RAS wild-type metastatic colorectal cancer","volume":"26","author":"Strickler","year":"2021","journal-title":"Oncologist"},{"key":"10.1016\/j.critrevonc.2022.103681_bib164","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/s10911-008-9079-3","article-title":"Role of ErbB4 in breast cancer","volume":"13","author":"Sundvall","year":"2008","journal-title":"J. Mammary Gland Biol. Neoplasia"},{"key":"10.1016\/j.critrevonc.2022.103681_bib165","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1002\/1878-0261.12012","article-title":"Multiregion ultra-deep sequencing reveals early intermixing and variable levels of intratumoral heterogeneity in colorectal cancer","volume":"11","author":"Suzuki","year":"2017","journal-title":"Mol. Oncology"},{"key":"10.1016\/j.critrevonc.2022.103681_bib166","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1007\/s40265-019-01165-2","article-title":"The evolving biomarker landscape for treatment selection in metastatic colorectal cancer","volume":"79","author":"Taieb","year":"2019","journal-title":"Drugs"},{"key":"10.1016\/j.critrevonc.2022.103681_bib167","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/s00280-016-3214-4","article-title":"LJM716 in Japanese patients with head and neck squamous cell carcinoma or HER2-overexpressing breast or gastric cancer","volume":"79","author":"Takahashi","year":"2017","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.critrevonc.2022.103681_bib168","doi-asserted-by":"crossref","DOI":"10.1158\/1535-7163.TARG-21-P197","article-title":"Abstract P197: An anti-HER3 antibody, HMBD-001, that uniquely binds to and blocks the HER3 heterodimerization interface, shows superior tumor growth inhibition in biomarker-defined preclinical cancer models including NRG1-fusion driven cancers","volume":"20","author":"Thakkar","year":"2021","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.critrevonc.2022.103681_bib169","doi-asserted-by":"crossref","first-page":"6751","DOI":"10.1158\/1078-0432.CCR-13-0423","article-title":"Increased TGF-alpha as a mechanism of acquired resistance to the anti-EGFR inhibitor cetuximab through EGFR-MET interaction and activation of MET signaling in colon cancer cells","volume":"19","author":"Troiani","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2022.103681_bib170","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1158\/2159-8290.CD-19-1014","article-title":"Targeting HER2 with trastuzumab deruxtecan: a dose-expansion, phase i study in multiple advanced solid tumors","volume":"10","author":"Tsurutani","year":"2020","journal-title":"Cancer Discov."},{"key":"10.1016\/j.critrevonc.2022.103681_bib171","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1038\/309418a0","article-title":"Human epidermal growth factor receptor cDNA sequence and aberrant expression of the amplified gene in A431 epidermoid carcinoma cells","volume":"309","author":"Ullrich","year":"1984","journal-title":"Nature"},{"key":"10.1016\/j.critrevonc.2022.103681_bib172","doi-asserted-by":"crossref","first-page":"2672","DOI":"10.1158\/0008-5472.CAN-11-3594","article-title":"HER3 is required for HER2-induced preneoplastic changes to the breast epithelium and tumor formation","volume":"72","author":"Vaught","year":"2012","journal-title":"Cancer Res."},{"key":"10.1016\/j.critrevonc.2022.103681_bib173","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1056\/NEJM198811103191902","article-title":"Neu-protein overexpression in breast cancer. Association with comedo-type ductal carcinoma in situ and limited prognostic value in stage II breast cancer","volume":"319","author":"van de Vijver","year":"1988","journal-title":"New Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2022.103681_bib174","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1007\/s40262-020-00858-2","article-title":"Population pharmacokinetics of MCLA-128, a HER2\/HER3 bispecific monoclonal antibody, in patients with solid tumors","volume":"59","author":"de Vries Schultink","year":"2020","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.critrevonc.2022.103681_bib175","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1517\/14712598.6.11.1229","article-title":"Panitumumab in colon cancer: a review and summary of ongoing trials","volume":"6","author":"Wainberg","year":"2006","journal-title":"Expert Opin. Biol. Ther."},{"key":"10.1016\/j.critrevonc.2022.103681_bib176","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1007\/s00280-014-2375-2","article-title":"Phase 1 and dose-finding study of patritumab (U3-1287), a human monoclonal antibody targeting HER3, in Japanese patients with advanced solid tumors","volume":"73","author":"Wakui","year":"2014","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.critrevonc.2022.103681_bib177","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1093\/carcin\/bgv049","article-title":"ERBB4 is over-expressed in human colon cancer and enhances cellular transformation","volume":"36","author":"Williams","year":"2015","journal-title":"Carcinogenesis."},{"key":"10.1016\/j.critrevonc.2022.103681_bib178","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1158\/1535-7163.MCT-12-0838","article-title":"Downregulation of HER3 by a novel antisense oligonucleotide, EZN-3920, improves the antitumor activity of EGFR and HER2 tyrosine kinase inhibitors in animal models","volume":"12","author":"Wu","year":"2013","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.critrevonc.2022.103681_bib179","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1159\/000452525","article-title":"MicroRNAs as regulators, biomarkers and therapeutic targets in the drug resistance of colorectal cancer","volume":"40","author":"Xie","year":"2016","journal-title":"Cell. Physiol. Biochem."},{"key":"10.1016\/j.critrevonc.2022.103681_bib180","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1038\/nchembio.1658","article-title":"Pharmacological targeting of the pseudokinase Her3","volume":"10","author":"Xie","year":"2014","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.critrevonc.2022.103681_bib181","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1038\/319230a0","article-title":"Similarity of protein encoded by the human c-erb-B-2 gene to epidermal growth factor receptor","volume":"319","author":"Yamamoto","year":"1986","journal-title":"Nature"},{"key":"10.1016\/j.critrevonc.2022.103681_bib182","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/mt.2012.184","article-title":"Cetuximab-mediated tumor regression depends on innate and adaptive immune responses","volume":"21","author":"Yang","year":"2013","journal-title":"Mol. Ther."},{"key":"10.1016\/j.critrevonc.2022.103681_bib183","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1038\/nrc3309","article-title":"The ERBB network: at last, cancer therapy meets systems biology","volume":"12","author":"Yarden","year":"2012","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.critrevonc.2022.103681_bib184","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0143132","article-title":"Combined analysis of plasma amphiregulin and heregulin predicts response to cetuximab in metastatic colorectal cancer","volume":"10","author":"Yonesaka","year":"2015","journal-title":"PloS One"},{"key":"10.1016\/j.critrevonc.2022.103681_bib185","doi-asserted-by":"crossref","first-page":"99ra86","DOI":"10.1126\/scitranslmed.3002442","article-title":"Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab","volume":"3","author":"Yonesaka","year":"2011","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.critrevonc.2022.103681_bib186","first-page":"13","article-title":"HER2-\/HER3-targeting antibody-drug conjugates for treating lung and colorectal cancers resistant to EGFR inhibitors","author":"Yonesaka","year":"2021","journal-title":"Cancers."},{"key":"10.1016\/j.critrevonc.2022.103681_bib187","doi-asserted-by":"crossref","unstructured":"Zenocutuzumab Shines in PDAC. Cancer discovery. 2021; 11: 1864.","DOI":"10.1158\/2159-8290.CD-NB2021-0356"},{"key":"10.1016\/j.critrevonc.2022.103681_bib188","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.semcdb.2016.08.033","article-title":"Colorectal cancer heterogeneity and targeted therapy: Clinical implications, challenges and solutions for treatment resistance","volume":"64","author":"Zhai","year":"2017","journal-title":"Semin. Cell Dev. Biol."},{"key":"10.1016\/j.critrevonc.2022.103681_bib189","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1158\/1535-7163.MCT-13-1033","article-title":"ERBB3\/HER2 signaling promotes resistance to EGFR blockade in head and neck and colorectal cancer models","volume":"13","author":"Zhang","year":"2014","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.critrevonc.2022.103681_bib190","first-page":"13","article-title":"miR-125b promotes colorectal cancer migration and invasion by dual-targeting CFTR and CGN","author":"Zhang","year":"2021","journal-title":"Cancers."},{"key":"10.1016\/j.critrevonc.2022.103681_bib191","doi-asserted-by":"crossref","first-page":"3884","DOI":"10.1074\/jbc.271.7.3884","article-title":"Transformation of NIH 3T3 cells by HER3 or HER4 receptors requires the presence of HER1 or HER2","volume":"271","author":"Zhang","year":"1996","journal-title":"J. Biol. Chem."}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842822001056?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842822001056?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T19:42:57Z","timestamp":1760902977000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842822001056"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":191,"alternative-id":["S1040842822001056"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2022.103681","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2022,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The HER family as therapeutic targets in colorectal cancer","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2022.103681","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"103681"}}